Intrathecal adenosine enhances the antinociception of Xylazine in goats

Mahmoud M. Abouelfetouh1,2, Eman Salah3,4, Lingling Liu1,5, Mingxing Ding1 and Yi Ding1*

Abstract
Background: The role of adenosine (AD) in neuromodulation of nociceptive signaling at the level of the spinal cord has been established in both preclinical and clinical models. Recently, the signaling pathway that involves adenosine 5-monophosphate activated protein kinase has been reported to mediate the antinociceptive effects of xylazine (XYL). The objective of this study was to investigate the antinociceptive, cardiorespiratory and hematological effects of intrathecal administration of combined XYL-AD in goats as compared to XYL alone. Six clinically healthy adult goats weighing 25 ± 2 kg were randomly assigned to one of three groups in a cross-over design. Goats were sedated with XYL (0.05 mg/kg, IM) in all groups. Ten min later, 0.9% saline solution [SAL group], XYL (0.05 mg/kg) [XYL group] or a combination of XYL (0.05 mg/kg) and AD (2000 µg) [XYL-AD group] was injected intrathecally. Antinociception scores and both cardiorespiratory and hematological parameters were measured before XYL sedation and intrathecal injection (baseline), and at 5, 10, 15, 30, 60, 90, 120 and 150 min thereafter.

Results: The XYL-AD group showed significantly earlier onset of antinociception [5 (5–7) min] than XYL [13 (12–14.25) min] (P = 0.031). The duration of complete antinociception in goats that received XYL-AD was significantly longer (P = 0.031) than that received XYL alone [65 (58.75–66.25) and 47.5 (43.75–51.25) min, respectively]. In both XYL and XYL-AD groups, heart rate (HR), arterial blood pressure (SAP, MAP and DAP) were significantly decreased (P < 0.05) compared to the baseline. Compared to the SAL group, a statistically significant reduction in HR from 10 to 150 min (P < 0.05) was detected in the XYL group contrary to the XYL-AD group. Differences in the hematological parameters among different groups were insignificant.

Conclusions: AD injected intrathecally interacts synergistically with XYL to promote antinociception in goats. This discovery supports the use of AD in combination with XYL in clinical trials.

Keywords: Adenosine, Antinociception, Cardiorespiratory parameters, Xylazine, Goats

Background
Adenosine (AD) is a purine nucleoside molecule that is formed from the breakdown of adenosine triphosphate (ATP) [1]. Adenosine influences a variety of biological responses when it binds to four G-protein coupled adenosine receptors A1, A2A, A2B and A3. These receptors are widely distributed throughout the body, but are especially concentrated within the cardiovascular, hematopoietic, and central nervous systems. Receptors can become activated by either endogenous or exogenous AD or its analogs [2, 3]. One of the many consequences of activation of spinal A1 and A2 receptors is the modulation of nociceptive signaling within the dorsal horn of the spinal cord [4–8]. Nociceptive input can be inhibited through several mechanisms, including presynaptic inhibition of excitatory neurotransmitters, hyperpolarization of spinal neurons by activation of K+ currents and inhibition of Ca2+ conductance [9–11].
Activation of A1 and A2 receptors also impacts the cardiovascular system. Binding of AD to A1 receptors inhibits catecholamine release, thereby slowing atrioventricular conduction whereas binding of AD to A2A reverses the anti-adrenergic effect and subsequently increases cardiac contractility. Recent reports have demonstrated that AD has the potential to induce tachycardia by triggering sympathetic excitation as well as catecholamine release [12–15]. In addition, administration of AD via infusion has been reported to induce tachycardia, increased hemoglobin concentration and decreased blood pressure in pregnant ewes [16]. It is possible that the reported change in hemoglobin is due to activation of A3 receptors, which stimulates proliferation of precursor cells for erythrocytes, granulocytes, and macrophages. This would alter cellular components of the peripheral blood [17, 18].

Xylazine (XYL) is an α2 adrenergic receptor agonist that is commonly administered as a sedative and antinociceptive agent in veterinary practice. Xylazine mediates pain management when it binds to receptors that are located pre- and postsynaptically on the nociceptive neurons within the dorsal horn of the spinal cord. Binding of xylazine to these receptors triggers a reduced response to sympathetic activation or intravascular norepinephrine [19].

Recent efforts have concentrated on the adenosine 5-monophosphate activated protein kinase (AMPK) signaling pathway as a means of modulating the antinociceptive effect of XYL [20]. It has also been theorized that the antinociceptive effects of XYL might be magnified if XYL is administered in combination with other analgesic and anesthetic agents, including opioids [21], lidocaine [22] and ketamine [23]. Regional antinociception achieved by intrathecal and epidural injections is commonly used in small ruminants. Intrathecal administration allows analgesic agents to bypass the meningeal barriers to reach the dorsal horn of the spinal cord to impact their actions [24].

To our knowledge, no published articles have determined the effects of intrathecal administration of combined XYL-AD in goats. Our objective was to document the antinociceptive, cardiorespiratory and hematological effects of this combination. We hypothesized that AD would provide synergistic antinociceptive when administered in combination with XYL.

**Results**

In this current study, intrathecal administration of XYL alone or combined with AD could induce complete antinociception of the umbilicus and caudal abdominal regions. The onset and duration of antinociception and antinociception scores were significantly different between the two groups. The XYL-AD group experienced significantly earlier onset of antinociception [5 (5–7) min] than the XYL group [13 (12–14.25) min (P=0.031)]. The duration of complete antinociception (score 3) induced in the XYL-AD group was significantly longer (P=0.031) than that induced in the XYL group [65 (58.75–66.25) and 47.5 (43.75–51.25) min, respectively] (Fig. 1). The antinociception scores were significantly higher in the XYL-AD group from 4 to 9 min and at 65 min (P<0.05) compared to the XYL group. Compared to the SAL group, the XYL-AD group showed a significant difference from 4 to 65 min. So did the XYL group, from 14 to 40 min (P<0.05) (Fig. 2).

In both the XYL and XYL-AD groups, heart rate (HR) significantly decreased (P<0.05) between 5 to 90 min after intrathecal administration as compared to baseline. Compared to the SAL group, the XYL group exhibited a statistically significant reduction in HR from 10 to 150 min (Fig. 3). Systolic, mean, and diastolic arterial pressures (SAP, MAP and DAP) reduced significantly (P<0.05) in both XYL and XYL-AD groups compared to the baseline and remained low for 120 min. Additionally, a significant decrease occurred in respiratory rate (RR) in both groups from 10 to 30 min and 15 to 30 min, respectively. There was non-significant change in hemoglobin oxygen saturation (SpO2) throughout the experimental period. Compared to the SAL group, the XYL-AD group showed a significant decrease in rectal temperature (RT) from 5 min, and the XYL group from 15 min through to completion of the experiment (150 min) (Table 1).

In both XYL and XYL-AD groups, white blood count (WBC), lymphocyte %, red blood count (RBC), hemoglobin concentration (HGB), hematocrit (HCT) and mean...
corpuscular volume (MCV) were lower, while mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC) and granulocyte % were higher compared to the baseline during the experiment (Table 2). In both groups, these hematological fluctuations were observed anywhere from 10 to 120 min. They returned to near-baseline by the 150 min mark.

**Discussion**

Intrathecal administration of AD combined with XYL produced fast onset and prolonged duration of antinociception. Our findings demonstrated that AD acts synergistically with XYL to enhance antinociception. This study provides the first report about the effectiveness of combined XYL-AD administered intrathecally in goats.
Table 1  Cardiorespiratory parameters at 5, 10, 15, 30, 60, 90, 120 and 150 min following intrathecal saline (SAL), xylazine (XYL) and xylazine-adenosine (XYL-AD) in XYL-sedated goats

| Parameter | Group  | Time after intrathecal administration (minutes) | Base b  | 5 | 10 | 15 | 30 | 60 | 90 | 120 | 150 |
|-----------|-------|------------------------------------------------|---------|---|----|----|----|----|----|-----|-----|
| HR (beats/min) | SAL | 106.1±7.9 | 84.5±4.8<sup>a</sup> | 85.3±3.8<sup>a</sup> | 83±3<sup>a</sup> | 84.3±4.8<sup>a</sup> | 87.5±10 | 95±6.9 | 96.5±7.7 | 100.5±9.8 |
| | XYL | 97.1±9.4 | 75.6±8<sup>a</sup> | 73±5<sup>ab</sup> | 70.6±8<sup>ab</sup> | 71.6±9.4<sup>ab</sup> | 72.5±8.6<sup>ab</sup> | 71.3±7.1<sup>ab</sup> | 74.1±6.7<sup>ab</sup> | 76.8±8.7<sup>ab</sup> |
| | XYL-AD | 99.1±10 | 76.5±8.1<sup>a</sup> | 77.6±7.6<sup>a</sup> | 76.5±8<sup>a</sup> | 74.6±7.7<sup>a</sup> | 80.1±6.4<sup>a</sup> | 81.3±10.5<sup>a</sup> | 83.8±6.5<sup>a</sup> | 88.1±8.4 |
| SAP (mmHg) | SAL | 118.5±9.2 | 94.1±7.1<sup>a</sup> | 98.8±8.6<sup>a</sup> | 101±11<sup>a</sup> | 110.3±11.3 | 105.8±10.6 | 107.1±4.3 | 108.3±9 | 116.8±12 |
| | XYL | 118.8±10.2 | 93.1±8.8<sup>a</sup> | 87.6±9.7<sup>a</sup> | 895±12.1<sup>a</sup> | 86.8±11<sup>ab</sup> | 84.8±7.9<sup>ab</sup> | 89.3±8.2<sup>ab</sup> | 101.6±11.9 | 113.1±12.5 |
| | XYL-AD | 121±105 | 88.8±16.1<sup>a</sup> | 85.5±11.8<sup>a</sup> | 79.1±12<sup>ab</sup> | 80.3±14.3<sup>ab</sup> | 86.1±12.8<sup>ab</sup> | 88.1±12.8<sup>ab</sup> | 95.3±12.3<sup>ab</sup> | 114.5±11.6 |
| MAP (mmHg) | SAL | 87.1±7.4<sup>a</sup> | 66.8±3.5<sup>a</sup> | 71.6±5<sup>a</sup> | 70.4±4<sup>a</sup> | 73.5±3<sup>a</sup> | 73.3±2.5 | 75.8±2 | 80.5±4 | 83.5±7.1 |
| | XYL | 85.6±7.5 | 66.6±3.5<sup>a</sup> | 64±6.3<sup>a</sup> | 67±6.3<sup>a</sup> | 61.2±5.5<sup>a</sup> | 64.1±4.9<sup>a</sup> | 63.6±5.2<sup>a</sup> | 71.1±5.2 | 78.5±7 | 79.1±54 |
| | XYL-AD | 86.3±4.9 | 66±6.8 | 64.5±5.1<sup>a</sup> | 61.1±7.1<sup>ab</sup> | 59.8±8.6<sup>ab</sup> | 63.5±5.1<sup>ab</sup> | 64.5±6.1<sup>ab</sup> | 72.8±4.6 | 81.5±7.8 |
| DAP (mmHg) | SAL | 71.8±7.7 | 53.5±3.7<sup>a</sup> | 58.6±4.8<sup>a</sup> | 54.8±3.7<sup>a</sup> | 56.3±2<sup>a</sup> | 59.1±2.3<sup>a</sup> | 60.3±2 | 66.8±5.9 | 67.1±5.7 |
| | XYL | 69.5±7.3 | 52.6±3.7<sup>a</sup> | 52.8±4.9<sup>a</sup> | 49.8±4.4<sup>a</sup> | 53.3±3.5<sup>a</sup> | 53.3±5<sup>a</sup> | 62.6±5.1 | 66.5±6.6 | 65.7±3 |
| | XYL-AD | 68.6±8 | 55.1±4.9<sup>a</sup> | 54.3±5.9<sup>a</sup> | 52.6±7.2<sup>a</sup> | 50.1±5.9<sup>ab</sup> | 52.6±4.5<sup>a</sup> | 60.3±6.2 | 62.8±7 | 65.5±10.5 |
| SpO₂ (%) | SAL | 94.5±2.2 | 95.2±2.2 | 94.5±2.2 | 94±2.7 | 93.5±2.4 | 95.3±13 | 94±3 | 95.3±13 | 94.6±24 |
| | XYL | 96.3±1.5 | 93.8±1.8 | 94.6±1.6 | 93.6±1.9 | 94.5±1 | 95.1±1.1 | 95.1±1.7 | 95±2 | 96.1±13 |
| | XYL-AD | 95.8±1.3 | 93.8±1.6 | 94.5±1.8 | 94.8±1.4 | 94.5±1.6 | 94±1.5 | 95.3±1 | 95±2.4 | 95.6±1 |
| RR (breaths/min) | SAL | 22.8±4.5 | 19±3.2<sup>a</sup> | 16.1±2.1<sup>a</sup> | 15±2<sup>a</sup> | 15.3±2.1<sup>a</sup> | 17±3 | 17±3.26 | 18.6±2.7 | 21.3±3 |
| | XYL | 23±4.5 | 17.1±3.5 | 16.5±3.2<sup>a</sup> | 14±3.7<sup>a</sup> | 15.1±3.1<sup>a</sup> | 19.1±3.9 | 17.5±3 | 20±4 | 21.3±8 |
| | XYL-AD | 23.1±4.9 | 18.8±2.2 | 19.1±3.7 | 17.6±3<sup>a</sup> | 16.3±3.7<sup>a</sup> | 14.6±3 | 19.1±3.4 | 193±3.7 | 21.3±8 |
| Parameter | Group  | Time after intrathecal administration (minutes) |  |  |  |  |  |  |  |
|-----------|--------|-----------------------------------------------|---|---|---|---|---|---|---|
|           |        | Base b  | 5    | 10   | 15   | 30   | 60   | 90   | 120  | 150  |
| RT (°C)   | SAL    | 39.3±0.12 | 39.2±0.09 | 39.1±0.09 | 39.1±0.05 | 39.03±0.05 | 38.9±0.07 | 38.9±0.05 | 38.7±0.11 | 38.7±0.08 |
|           |  | p=0.002 | p=0.004 | p=0.001 | p<0.001 | p<0.001 | p<0.001 | p<0.001 | p<0.001 |
|           | XYL    | 39.2±0.05 | 39.1±0.05 | 39±0.05 | 38.9±0.07 | 38.6±0.07 | 37.8±0.07 | 37.6±0.08 | 37.5±0.06 | 37.5±0.04 |
|           |  | p=0.001 | p=0.001 | p<0.001 | p<0.001 | p<0.001 | p<0.001 | p<0.001 | p<0.001 | p<0.001 |
|           | XYL-AD | 39.2±0.07 | 39.1±0.07 | 39±0.07 | 38.9±0.07 | 38.6±0.05 | 38.2±0.05 | 37.9±0.13 | 37.9±0.13 | 38.1±0.08 |
|           |  | p=0.048 | p=0.049 | p=0.001 | p<0.001 | p<0.001 | p<0.001 | p<0.001 | p<0.001 | p<0.001 |

HR heart rate; SAP systolic arterial blood pressure; MAP mean arterial blood pressure; DAP diastolic arterial blood pressure; SpO₂ hemoglobin oxygen saturation; RR respiratory rate; RT rectal temperature

Data is expressed as mean ± SD (n = 6)

* significantly different from the base value (p < 0.05) within each group; † values taken before intramuscular xylazine and intrathecal injection

* significantly different from the SAL group at the same time point (P < 0.05)
Table 2 Hematological parameters at 5, 10, 15, 30, 60, 90, 120 and 150 min following intrathecal saline (SAL), xylazine (XYL) and xylazine- adenosine (XYL-AD) in XYL-sedated goats

| Parameter       | Group   | Time after intrathecal administration (minutes) | Base | 5     | 10     | 15     | 30     | 60     | 90     | 120    | 150    |
|-----------------|---------|-------------------------------------------------|------|-------|--------|--------|--------|--------|--------|--------|--------|
| WBC (x 10³/L)   | SAL     | 13.3 ± 2.1                                      | 12.5 ± 1.8 | 12.1 ± 1.7 | 12.2 ± 1.9 | 12.3 ± 1.7 | 12.8 ± 1.7 | 12.3 ± 1.6 | 12.1 ± 1.6 | 12.3 ± 2.2 |
|                 | XYL     | 11.8 ± 1.4                                      | 11.5 ± 1.7 | 11.1 ± 1.4 | 10. ± 1.8 | 9.5 ± 1.6³ | 10.1 ± 1.3³ | 11.1 ± 1.5³ | 11.5 ± 1.8 | 12.1 ± 1.4 |
|                 | XYL-AD  | 12.3 ± 2.8                                      | 12.1 ± 2.5 | 11.5 ± 2.5 | 9.5 ± 2.3³ | 8.8 ± 2.4³ | 9.1 ± 2.5³ | 10.3 ± 2.8³ | 11.1 ± 2.9³ | 12.6 ± 2.6 |
| Lymphocyte %    | SAL     | 50.8 ± 4.1                                      | 50.3 ± 3.8 | 49.7 ± 3.9 | 49.5 ± 4.1 | 49.6 ± 3.8³ | 49.4 ± 3.4³ | 49 ± 4     | 49.8 ± 3.5 | 50.1 ± 3.6 |
|                 | XYL     | 50.8 ± 3.4                                      | 50.3 ± 3.3 | 49.8 ± 3.6 | 48.8 ± 3.6³ | 47.8 ± 3.6³ | 46.5 ± 2.5³ | 47 ± 2.8³ | 48.3 ± 2.4³ | 49.1 ± 2.4³ |
|                 | XYL-AD  | 50 ± 4.2                                        | 49.6 ± 4.5 | 49 ± 4.4 | 48.2 ± 4.5³ | 46.5 ± 4.4³ | 45.4 ± 4.4³ | 46.3 ± 4.5³ | 47 ± 4.4³ | 48 ± 4.2³ |
| Granulocyte %   | SAL     | 37.6 ± 4.2                                      | 37.5 ± 4  | 39.8 ± 4.8 | 41.8 ± 3.7 | 43.8 ± 3.8³ | 44.1 ± 3.9³ | 44.8 ± 2.4³ | 41.6 ± 3.4³ | 39 ± 3³ |
|                 | XYL     | 37.8 ± 3.4                                      | 38.3 ± 3.6 | 40.6 ± 5.2 | 43.1 ± 4.1 | 47.5 ± 5.3³ | 46.5 ± 4.3³ | 48.5 ± 4.3³ | 42.4 ± 5.3³ | 41.6 ± 4.8³ |
|                 | XYL-AD  | 35.1 ± 2.9                                      | 35.5 ± 2.8 | 36.6 ± 1.9 | 37.6 ± 2.9³ | 38.9 ± 3.7³ | 41.6 ± 2.9³ | 40.1 ± 2.5³ | 39.3 ± 2.4³ | 38.5 ± 2.6³ |
| RBC (x 10¹²/L)  | SAL     | 20.1 ± 2.1                                      | 20.2 ± 2.3 | 19.6 ± 2.5 | 18.6 ± 2.1³ | 16.8 ± 1.8³ | 17.1 ± 1.6³ | 18.1 ± 1.6 | 18.1 ± 2.3 | 19.3 ± 1.9³ |
|                 | XYL     | 20 ± 1.4                                        | 20.0 ± 0.8 | 19.6 ± 1.5 | 17.8 ± 1.1³ | 16.3 ± 1.2³ | 17.3 ± 1.2³ | 17.6 ± 0.8³ | 18.3 ± 0.5 | 19.5 ± 1³ |
|                 | XYL-AD  | 19.3 ± 3                                        | 19.2 ± 2.5 | 18.5 ± 2.5 | 16.5 ± 2.4³ | 15.2 ± 2.2³ | 15.8 ± 2.2³ | 16.8 ± 2.1³ | 17.3 ± 2.5³ | 18.5 ± 2.2³ |
| HCT (%)         | SAL     | 295.1 ± 1.7                                     | 293.2 ± 2.3 | 281.2 ± 2.4 | 273.2 ± 2³ | 27.1 ± 2³ | 27 ± 2³ | 27.8 ± 1.9³ | 27.5 ± 1.7³ | 28.6 ± 1.2³ |
|                 | XYL     | 296.2 ± 2.7                                     | 295.3 ± 3 | 273.2 ± 2.6³ | 26 ± 2.2³ | 25 ± 2.3³ | 26 ± 1.8³ | 26.8 ± 1.7³ | 29.3 ± 2.3³ | 29.5 ± 2.8³ |
|                 | XYL-AD  | 283.2 ± 2.7                                     | 276.2 ± 2.8 | 266.2 ± 2.8³ | 256.2 ± 2.8³ | 24.6 ± 2.6³ | 25.3 ± 3.1³ | 26.3 ± 2.1³ | 27.2 ± 2.2³ | 28.1 ± 2.5³ |
| HGB (g/dL)      | SAL     | 9 ± 0.6                                         | 8.7 ± 0.8 | 8.4 ± 0.9 | 8 ± 0.8³ | 8.1 ± 0.9³ | 7.8 ± 0.9³ | 7.9 ± 0.8³ | 8.2 ± 0.7³ | 8.5 ± 0.8³ |
|                 | XYL     | 9.2 ± 0.6                                       | 9.0 ± 0.8 | 8.7 ± 0.9 | 8.2 ± 0.8³ | 7.8 ± 0.9³ | 7.6 ± 0.7³ | 7.8 ± 0.8³ | 8.2 ± 0.9³ | 8.6 ± 1³ |
|                 | XYL-AD  | 9.4 ± 0.5                                       | 9.3 ± 0.5 | 8.9 ± 0.6³ | 8.5 ± 0.8³ | 8.3 ± 0.5³ | 8.2 ± 0.6³ | 8.6 ± 0.6³ | 8.6 ± 0.7³ | 8.9 ± 0.6³ |
| MCV (fL)        | SAL     | 22.5 ± 3                                        | 22.1 ± 1.7 | 21.3 ± 1.5 | 20 ± 1.4³ | 19.5 ± 1.1³ | 20 ± 1.4 | 21.3 ± 1.5 | 21.5 ± 1.2³ | 22 ± 1.2³ |
|                 | XYL     | 22.3 ± 1.7                                      | 21.8 ± 2.2 | 21.6 ± 2.5 | 20.2 ± 1.5³ | 19.8 ± 1.4³ | 20.3 ± 1.6³ | 21 ± 1.6³ | 21.8 ± 1.7³ | 22.1 ± 1.2³ |
|                 | XYL-AD  | 21.5 ± 3                                        | 21.2 ± 2.8 | 20.7 ± 2.8 | 19.9 ± 3.3³ | 19.1 ± 3.4³ | 19.5 ± 3.4³ | 20.4 ± 3.2³ | 21 ± 3.1³ | 21.2 ± 2.8³ |
| MCH (pg)        | SAL     | 78 ± 0.9                                        | 8.0 ± 0.8 | 7.8 ± 0.7 | 8.8 ± 1 | 9.9 ± 1³ | 10.0 ± 0.8³ | 10.4 ± 1.1³ | 94.9 ± 0.9³ | 84.1³ |
|                 | XYL     | 7.5 ± 0.6                                       | 7.6 ± 0.8 | 8.0 ± 0.8 | 9.5 ± 1³ | 10.3 ± 1³ | 10.8 ± 1.2³ | 10.6 ± 1.2³ | 96 ± 1.2³ | 86.1² |
|                 | XYL-AD  | 7 ± 1.3                                        | 7.1 ± 1.4 | 7.4 ± 1.1 | 8.8 ± 1.2³ | 9.3 ± 1³ | 10 ± 1.1³ | 93 ± 0.9³ | 85 ± 1³ | 7.5 ± 1³ |
Previous studies have reported that intrathecal administration of AD increased antinociceptive threshold in rats that were exposed to acute thermal [25], and surgical pain [26]. Intrathecal administration of AD at a dose of 2000 µg was reported to reduce pain and produce a clinically relevant reduction of electrically induced temporal summation in humans [8, 27]. Additionally, a combination of intrathecal clonidine and AD has reportedly reduced hypersensitivity in patients with chronic regional pain syndrome [8]. A prior study also revealed that AD could potentiate the antinociceptive effect of acupuncture, which may improve the clinical application of integrative medicine [7]. XYL influences antinociception by binding to alpha-2 adrenergic receptors and exerting a local anesthetic-like action within the spinal cord [28, 29]. AD reduces neuronal excitability and nociceptive input in the spinal cord via activating A1 and A3 receptors, leading to modulation of Ca2+/K+ ions and γ-aminobutyric acid (GABA) neurotransmission [30–32]. Recently, the AMPK signaling pathway has been reported to contribute in the central antinociceptive mechanism of XYL [20]. Following intrathecal administration of detomidine-lidocaine, the onset and duration of antinoiception was 13.00 ± 1.89 min and duration for 66.25 ± 10.60 min, respectively [33]. Moreover, XYL at a dose of 0.1 mg/kg produced a complete antinociception with an onset of 9.5 ± 2.6 min and duration of 88.3 ± 15 min [34]. Compared to the previous studies, the combination of XYL at a dose of 0.05 mg/kg and AD produced earlier onset of antinociception, indicating AD act collaboratively with XYL to improve the antinociception.

The significant reduction in HR, SAP, MAP and DAP in both XYL and XYL-AD groups can be attributed to the depressant central and peripheral actions of XYL on sympathetic activity and catecholamines release [35]. Similar results after intrathecal or epidural administration of XYL have been reported in goats [23, 36]; sheep [37, 38]; cattle [39] and buffaloes [40]. A significant decrease in HR was observed in the XYL group, not in the XYL-AD group, as compared to the SAL group. This finding could be explained due to activation of AD A2 receptors that increase cardiac contractility directly or indirectly via attenuating antiadrenergic effect mediated by AD A1 receptors [41]. Previous studies reported that AD could elicit tachycardia in conscious man [13], and dogs [15]. Activation of central sympathetic tone might be also implicated in the AD-induced tachycardia [13]. Furthermore, AD infusion resulted in twofold increase in plasma circulating norepinephrine [42]. In this current study, AD could be slowly released into the circulation following intrathecal administration, so it could exert its systemic action at the level of the spinal cord and periphery. RR and RT were decreased in both XYL and XYL-AD groups and non-significant difference detected between the two groups. XYL administration has been reported to induce depression in respiratory [43] and thermoregulatory centers as well as reduction in the metabolic rate due to profound sedation and muscle relaxation [36]. There were no evidence of respiratory depression and /or hypothermia associated with AD administration [12, 16].

Both XYL and XYL-AD groups experienced significant alterations in RBC, WBC, lymphocyte %, HCT, HGB, MCV and granulocyte %, MCH and MCHC compared to the baseline. However, differences between the XYL and XYL-AD groups were insignificant. AD has not been reported to have a hematological influence [2], indicating XYL has been implicated in most changes in the peripheral blood constituents. These findings coincide with other studies reporting the hematological effect of systemic and epidural XYL administration in goats and horses [44–46]. Sequestration of blood in the spleen and other reservoir sites like liver, muscle, and skin as a result of decreased sympathetic outflow

### Table 2 (continued)

| Parameter | Group      | Time after intrathecal administration (minutes) | Base b | 5     | 10    | 15     | 30     | 60     | 90     | 120    | 150    |
|-----------|------------|-----------------------------------------------|--------|-------|-------|--------|--------|--------|--------|--------|--------|
| MCHC (g/dL) | SAL        |                                               | 45.8 ± 2.6 | 45.1 ± 3.1 | 45.4 | 46.8 ± 2.8 | 46.1 ± 3.2 | 48.2 ± 2.8 | p = 0.004 | 48.8 ± 1.9 | p = 0.010 | 46.5 ± 2.1 | 46.2 ± 2.2 |
|           | XYL        |                                               | 44.5 ± 3.9 | 44.4 ± 4.1 | 45.8 ± 4.3 | 48.6 ± 4.3 | p = 0.002 | 50.6 ± 4.3 | p < 0.001 | 52.8 ± 3.8 | p < 0.001 | 50.8 ± 4.4 | 47.6 ± 4.1 | 45.3 ± 3.6 |
|           | XYL-AD     |                                               | 47.1 ± 3.7 | 46.6 ± 3.3 | 47.8 ± 4.4 | 50.8 ± 3.7 | p < 0.001 | 52.5 ± 3.9 | p < 0.001 | 54.3 ± 3.9 | p < 0.001 | 52.5 ± 3.5 | 50.6 ± 3.6 | 48.1 ± 3.7 |

WBC white blood count; RBC red blood count; HCT hematocrit; HGB hemoglobin; MCV mean corpuscular volume; MCH mean corpuscular hemoglobin; MCHC mean corpuscular hemoglobin concentration

Data is expressed as mean ± SD (n = 6)

* significantly different from the base value (P < 0.05) within each group; † values taken before intramuscular xylazine and intrathecal injection

b significantly different from the SAL group at the same time point (P < 0.05)
following XYL administration could be attributed to the decrease in RBC, HCT and HGB [47, 48]. Furthermore, XYL sedation has been reported to decrease RBC, WBC, MCV, HCT and HGB [36, 44], which might be explained by xylazine-induced hemolysis and hemodilution caused by fluid displacement from the lumen into the blood circulation. Alpha2-adrenergic agonists have been suggested to activate pulmonary intravascular macrophages and stimulate a series of inflammatory events resulting in recruitment of leukocytes in the lung circulation [49, 50]. This mechanism might be implicated in a decrease in WBC within the peripheral circulation. Moreover, XYL immobilization may induce a stressful condition, which could trigger adrenocortical function and glucocorticoid (GC) release [51]. The GC could provoke suppression of lymphoid tissues, resulting in decreased proliferation and apoptosis of lymphocytes. Moreover, XYL has a direct immunosuppressive effect on spleen via inhibiting splenocytes proliferation as well as inducing lymphocyte death [52]. Even though WBC and lymphocytes were significantly decreased, granulocytes (polymorphonuclear leukocytes; PMNs) were significantly increased [53]. The XYL itself and/or the induced GC may be attributed to the increase in circulatory PMNs via several biologic effects, including decreased margination of PMNs, delayed extravasation of PMNs into tissue, delayed rate of apoptosis and the release of immature neutrophils from the bone marrow into the circulation [54, 55]. The effects of XYL on blood cellular indices are at times contradictory and the exact mechanisms that underlie the changes in parameters remain undetermined.

The small sample size in this study may have limited the value of observations as a true representation of the goat population. In addition, a comprehensive evaluation would be provided if sedation score data was available in this study, but the main objective of this study was to document the antinociceptive, cardiorespiratory and hematological effects of intrathecal XYL (0.05 mg/kg) and AD (2000 µg) combination in goats. Moreover, additional studies were needed to explore the effect of intrathecal AD alone as well as explain the antinociceptive synergism of the XYL and AD.

Conclusion
Intrathecal administration of AD (2000 µg) combined with XYL (0.05 mg/kg) enhances antinociception in goats. The onset of antinociception was faster, and the duration was longer as compared with intrathecal administration of XYL alone. Therefore, our data support using XYL-AD in clinical trials in goats to improve delivery and onset of antinociception.

Material and methods
Animals
Six clinically healthy adult female goats between the ages of 14.3 ± 0.7 months and weighing 25 ± 2 kg were included in this study. For the purposes of this study, a clinically healthy animal was defined as one that underwent comprehensive physical examination and tested within the normal reference ranges for complete blood count and biochemical profile. The goats were purchased locally and brought into experimental research unit one week prior to the experiment for daily acclimatization to handling and the environmental design. The animals were fed maize, wheat bran and alfalfa hay and gained free access to water. Goats were denied access to food or water for 8 h prior to the experiment. All experiments were carried out in the morning. At the conclusion of the study, goats were transferred to the Veterinary Teaching Farm to be maintained by the College of Veterinary Medicine, Huazhong Agricultural University. This study was approved by the Animal Experimental Ethical Inspection of Laboratory Animal Center, Huazhong Agricultural University (ID number: HAZUGO-2021-0001).

Study design
This experimental study made use of prospective, randomized crossover design. Goats were sedated with XYL (0.05 mg/kg, IM; Xylaject 2%, Adwia, Egypt) in all groups. Ten min later, 0.9% saline solution (SAL group), XYL (0.05 mg/kg) (XYL group) or a combination of XYL (0.05 mg/kg) and AD (2000 µg/animal; Adenocor® 3 mg/mL; Sanofi, UK) (XYL-AD group) was injected intrathecally with a 7-day washout period. The agent(s) that were administered into each group were diluted in 3 mL saline (approx. 1 mL/7.5 kg). The size of needle used for intrathecal injection was 20 G and 3.5 cm in length. The lumbosacral region was clipped and prepared aseptically using betadine antiseptic solution (Betadine®, Mundipharma Pharmaceuticals Ltd). The skin and subcutaneous tissue over the lumbosacral region was infiltrated with Debocaine 2% (Sigma-Tec Pharmaceutical Industries). Following XYL sedation, the goats were positioned in right lateral recumbency for intrathecal injection. The needle was pointed at the level of the lumbosacral junction along the median line and directed into the spinal cord. The subarachnoid space was verified by free flow of cerebrospinal fluid through the hub of the needle. Antinociception scores and cardiorespiratory
and hematological parameters were measured before XYL sedation and intrathecal injection (baseline), and at 5, 10, 15, 30, 60, 90, 120 and 150 min after intrathecal injection (Fig. 4).

Antinociception scores measurement
An examiner who was blinded to drug treatments assessed the onset and duration of antinociception using pinprick needle stimulation at the level of umbilicus (2–4 cm from the midline at the level of umbilical stump) and caudal abdomen (2–4 cm from the midline midway between the umbilicus and pubic symphysis) using a modified scoring system of 0–3 (Appendix) [34]. In this current study, intrathecal injection was performed with the animal in the right lateral recumbency. Because the injected drugs tend to affect the spinal nerves suppling the downside, we tested for antinociception in the right umbilicus and caudal abdominal regions. A sum of 3 pinpricks using 23 g needle was applied through the skin, subcutaneous and muscular layers so that at each layer the antinociceptive response could be assessed. Purposeful reactions of head, neck, trunk, or limbs was defined as positive nociceptive reactions [56]. Following intrathecal injection, pinprick testing was done at 1-min intervals till occurrence of the onset of complete antinociception, and then at 5-min intervals until sensation was restored. The onset of antinociception was considered to be the time from intrathecal injection to complete loss of sensation (score 3), while the time from the onset to regain a moderate level of sensation (score 2) was defined as the duration of antinociception.

Cardiorespiratory parameters and rectal temperature
HR (beats/min), non-invasive arterial blood pressures (SAP, MAP and DAP; mmHg), SpO₂ (%), RR (breaths/min) as well as RT (°C) were measured using a multi-parameter 3-lead electrocardiogram (ECG) patient monitor (Mindray MEC-1200 Vet, Louisiana, US). In order to monitor blood pressure, an appropriately sized cuff (width was about 40% of the circumference of the limb) was positioned around the left metacarpal artery with the proximal end of the cuff 2.5 cm distal to the carpus [57].

Hematological parameters
Blood samples (2 mL) were obtained from the jugular vein using single-use syringes and immediately placed in 3-mL glass tubes containing the anticoagulant ethyldiaminetetraacetic acid (EDTA). The blood indices, including WBC (× 10⁹/L), lymphocytes %, granulocytes %, RBC (× 10¹²/L), HCT (%), HGB (g/dL), MCV (fl), MCH (pg) and MCHC (g/dL) were determined using automated haematology analyzer (Mindary, BC-2800 Vet, Shenzhen, P.R.China).

Statistical analysis
Statistical tests were performed using GraphPad Prism software version 8.0. The cardiorespiratory and hematological data were expressed as mean ± standard deviation (SD). The Kolmogorov–Smirnov test was used to confirm the normal distribution of data. Two-way ANOVA for repeated measures was used with Turkey’s post-hoc test to compare variables between groups. One-way ANOVA was used with Dunnett’s post-hoc test to compare variables within each group. Data of the antinociception scores, onset, and duration of antinociception were expressed as median and interquartile range [IQR] and compared using Friedman test with Dunn’s post-hoc test. The differences were considered significant at P < 0.05.
Appendix

Table 3

| Score | Description |
|-------|-------------|
| 0     | None: Presence of pain sensation in response to skin pinprick |
| 1     | Mild: Absence of pain sensation in response to skin pinprick |
| 2     | Moderate: Absence of pain sensation in response to subcutaneous pinprick |
| 3     | Complete: Absence of pain sensation in response to muscle pinprick |

Modified after DeRossi et al. 2002

Abbreviations:
AD: Adenosine; ARs: Adenosine receptors; AMPK: Adenosine 5-monophosphate activated protein kinase; ATP: Adenosine triphosphate; DAP: Diastolic blood pressure; ECG: Electrocardiogram; EDTA: Ethyldiaminetetraacetic acid; HCT: Hematocrit; HGB: Hemoglobin concentration; HR: Heart rate; GABA: Gamma aminobutyric acid; GC: Glucocorticoid; MAP: Mean blood pressure; HCT: Hematocrit; HGB: Hemoglobin concentration; PMNs: Polymorphonuclear leukocytes; HCC: Hemoglobin oxygen saturation; WBC: White blood cell count; XYL: Xylazine.

Acknowledgements
We gratefully acknowledge the ongoing collaboration and assistance provided by Department of Obstetrics and Surgery, College of Veterinary Medicine, Huazhong Agricultural University.

Authors’ contributions
Conceptualization, Y.D and M.D.; methodology, M.M.A; software, M.M.A; validation, M.M.A, E.S, L.L; investigation, M.M.A, E.S, and L.L.; resources, Y.D and M.D; data curation, M.M.A, E.S and L.L; writing- original draft preparation, M.M.A, E.S, L.L.; writing-review and editing, Y.D and M.D.; visualization, Y.D.; supervision, Y.D and M.D.; project administration, Y.D and M.D.; funding acquisition, Y.D and M.D. All authors have read and agreed to the published version of the manuscript.

Funding
National Natural Science Foundation of China (NO: 32072938, 31802255 and 31972756).

Availability of data and materials
The data presented in this study are available on request from the corresponding author.

Declarations
Ethics approval and consent to participate
This study was approved by the animal experimental ethical inspection of laboratory animal Center, Huazhong agricultural University (ID number: HAZUGO-2021-0001). The study was carried out in compliance with the ARRIVE and relevant guidelines e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe.

Consent for publication
Not applicable.

Competing interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author details
1 College of Veterinary Medicine, Huazhong Agricultural University, No.1, Shizishan Street, Hongshan District, Wuhan 430070, Hubei Province, China. 2 Department of Surgery, Radiology and Anaesthesiology, Faculty of Veterinary Medicine, Benha University, Mohshohor, Toukh 13736, Egypt. 3 National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAD Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan 430070, Hubei Province, China. 4 Department of Pharmacology, Faculty of Veterinary Medicine, Benha University, Mohshohor, Toukh 13736, Egypt. 5 Clinical Veterinary Laboratory, College of Veterinary Medicine, Henan University of Animal Husbandry and Economy, Zhengzhou 450046, Henan Province, China.

Received: 19 June 2021 Accepted: 14 February 2022
Published online: 17 March 2022

References
1. Mahler GS. Adenosine. In: Brittain HG, editor. Analytical profiles of drug substances and excipients, vol. 25. California: Academic Press; 1998. p. 1–37.
2. Effendi WI, Nagano T, Kobayashi K, Nishimura Y. Focusing on adenosine receptors as a potential targeted therapy in human diseases. Cells. 2020;9(3):785.
3. Madera T, Koo B.J. Adenosine A1 and A2a receptors modulate insulinemia, glyceremia, and lactatemia in fetal sheep. Am J Physiol Regul Integr Comp Physiol. 2009;296(3):693–701.
4. Reeve AJ, Dickenson AH. The roles of spinal adenosine receptors in the control of acute and more persistent nociceptive responses of dorsal horn neurones in the anaesthetized rat. Br J Pharmacol. 1995;116(4):2211–8.
5. Dickenson AH, Suzuki R, Reeve AJ. Adenosine as a potential analgesic target in inflammatory and neuropathic pains. CNS Drugs. 2000;13:77–85.
6. Hayashida M, Fukuda K, Fukunaga A. Clinical application of adenosine and ATP for pain control. J Anesth. 2005;19(3):225–35.
7. Goldman N, Chen M, Fujita T, Xu Q, Peng W, Liu W, et al. Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci. 2010;13:883–8.
8. Rauck RL, North J, Eisenach JC. Intrathecal clonidine and adenosine: effects on pain and sensory processing in patients with chronic regional pain syndrome. Pain. 2015;156(1):88–95.
9. Patel MK, Pinnock BD, Lee K. Adenosine exerts multiple effects in dorsal horn neurones of the adult rat spinal cord. Brain Res. 2001;920(1–2):19–26.
10. Li X, Eisenach JC. Adenosine reduces glutamate release in rat spinal synaptosomes. J Am Soc Anesthesiol. 2005;103(5):1060–5.
11. Tian L, Ji G, Wang C, Bai X, Lu Y, Xiong L. Excitatory synaptic transmission in the spinal substantia gelatiosa is under an inhibitory tone of endog-

CNS Drugs.
26. Zahn PK, Straub H, Wenk M, Pogatzki-Zahn EM. Adenosine A1 but Not A2a Receptors Potentiates Stimulatory Effects of IL-3, SCF, and GM-CSF on Mouse Granulocyte-Macrophage Hematopoietic Progenitor Cells. Physiol Res. 2009;58(2):247–52.

27. Eisenach JC, Rauck RL, Curry R. Intrathecal, but not intravenous adenosine agonists in regulation of hematopoiesis. Molecules. 2011;16(1):675–85.

28. Rostami M, Vesal N. The effects of adding epinephrine or xylazine to xylazine premedication on the dose and quality of anesthesia induction and pulmonary effects of subarachnoid and epidural xylazine-lidocaine in sedated horses. Vet Res Commun. 2007;31(7):847–61.

29. Robinson EP, Natalini CC. Intrathecal adenosine: interactions with spinal cord neurons and neurotransmitters in rat models of acute nociception and post-operative hypersensitivity. J Am Soc Anesthesiol. 1999;90(5):1413–21.

30. Wu WP, Hao JX, Halldner L, Lövdahl C, DeLander GE, Wiesenfeld-Hallin Z, et al. Changes in central nervous system of rats. PLoS One. 2016;11(4):e0153169.

31. Yoon MH, Bae HB, Choi J II. Antinociception of intrathecal adenosine monophosphate-activated protein kinase pathway in the central nervous system of rats. Physiol Res. 2009;58(2):397–806.

32. Borea PA, Gessi S, Merighi S, Varani K. Adenosine as a multi-signalling agonist in regulation of hematopoiesis. Molecules. 2011;16(1):675–85.

33. Zayed M, Mahmoud E, Khalil A, Salah M, Moustafa M, Youssef M, et al. Adenosine A2a receptor agonists on cardiac contractility. Am J Physiol Cell Physiol. 2005;32(5):297–307.

34. DeRossi R, Gaspar EB, Junqueira AL, Beretta MP. A comparison of two operative hypersensitivity. J Am Soc Anesthesiol. 1999;90(5):1413–21.

35. Posner LP. Sedatives and tranquilizers. In: Riviere JE, Papich MG, editors. Veterinary pharmacology and therapeutics. 10th ed. Hoboken: John Wiley & Sons; 2018. p. 524–50.

36. Kinjavdekar P, Amarpal GRS, Aithal HP, Pawde AM. Physiologic and biochemical effects of subarachnoidally administered xylazine and detomidine in goats. Vet Res Commun. 2003;47(2):111–12.

37. Boere PA, Varzea A, Meirelles J, Streitová D, Znojil V. Activation of Adenosine A1 Receptors Potentiates Stimulatory Effects of IL-3, SCF, and GM-CSF on Mouse Granulocyte-Macrophage Hematopoietic Progenitor Cells. Physiol Res. 2009;58(2):247–52.

38. Abouelfetouh MM, Liu L, Salah E, Sun R, Nan S, Ding M, et al. The Effect of xylazine premedication on the dose and quality of anesthesia induction with alfalone in goats. Animals. 2021;11(1):723.

39. St Jean G, Skarda RT, Muir WW, Hofsis GF. Caudal epidural analgesia induced by xylazine administration in cows. Am J Vet Res. 1990;51(8):1233–6.

40. Shokry MM, Elkasapy AH. Epidural anesthesia in Egyptian water buffalo (Bubalus bubalis): a comparison of lidocaine, xylazine and a combination of lidocaine and xylazine. Vet Anaesth Analg. 2018;45(5):707–10.

41. Chandraskeara PC, McIntosh VJ, Cao FX, Lasley RD. Differential effects of adenosine A2A and A2B receptors on cardiac contractility. Am J Physiol Circ Physiol. 2010;299(6):2082–9.

42. Dhallia AK, Wong MW, Wang WQ, Biagioni I, Belardinielli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther. 2006;316(2):695–702.

43. Athial HP, Pratap AK, Singh GR. Clinical effects of epidurally administered ketamine and xylazine in goats. Small Rumin Res. 1997;24:65–64.

44. Mogoa EG, Stegmann GF, Guthrie AJ, Swain GE. Clinical, cardiopulmonary and haemodynamic effects of xylazine in goats after acute exposure to different environmental temperature and humidity conditions. J S Afr Vet Assoc. 2000;71(3):153–9.

45. Ismail ZB, Jawaresh A, Al-Majali A. Effects of xylazine–ketamine–diazepam anesthesia on blood cell counts and plasma biochemical values in sheep and goats. Comp Clin Pathol. 2010;19:571–4.

46. Shaffar T, Al Mubarak A, Eidi H, El-Bahr SM. Seasonal effects on some clinical and hematological parameters and blood cortisol level in sedated Arabian horses with xylazine. Equine Vet Sci. 2020;84:102835.

47. Wilson DV, Evans AT, Carpenter RE, Mullineaux DR. The effect of four anesthetic protocols on splenic size in dogs. Vet Anaesth Analg. 2004;31(1):102–8.

48. Sutil DV, Mattoso CRS, Volpato J, Weint NC, Costa A, Antunes RR, et al. Hemin in ruminants. J Vet Pharmacol Ther. 2021;44(4):746–54.

49. Abouelfetouh MM, Salah E, Ding M, Ding Y. Application of adenosine agonists combined with anesthetics and their implication in pulmonary intravascular macrophages-insulted pulmonary edema and hypoxemia in ruminants. J Vet Pharmacol Ther. 2021;44(4):478–502.

50. Celly CS, Atwal OS, McDowell WN, Black WD. Histopathologic alterations induced in the lungs of sheep by use of alpha2-adrenergic receptor agonists. Am J Vet Res. 1999;60(2):154–61.

51. Chao CC, Brown RD, Defos LF. Effects of xylazine immobilization on biochemical and endocrine values in white-tailed deer. J Wildl Dis. 1984;20(4):328–32.

52. Cupić V, Ćaćić M, Pavićić L, Vučević D, Varagić VM. Immuno-modulatory effects of xylazine, an α2-adrenergic agonist, on rat spleen cells in culture. J Neuroimmunol. 2001;113(1):19–29.

53. Singh P, Pratap K, Kinjavdekar P, Athial HP, Singh GR. Effects of xylazine, lignocaine and their combination for lumbar epidural analgesia in water buffalo calves (Bubalus bubalis). J S Afr Vet Assoc. 2005;76(3):151–8.

54. Herrera-García AM, Domínguez-Luis MJ, Arce-Franco M, Armas-González E, de la Rosa DA, Machado JD, et al. Prevention of neutrophil extravasation by α2-adrenoceptor-mediated endothelial stabilization. J Immunol. 2014;193(6):3023–35.

55. Obinata H, Yokomizo T, Shimizu T, Izumi T. Glucocorticoids up-regulate leukotriene B4 receptor-1 expression during neutrophilic differentiation of HL-60 cells. Biochem Biophys Res Commun. 2003;309(1):114–9.

56. Dehkhordi SH, Bigham-Sadegh A, Gerami R. Evaluation of anti-nociceptive effect of epidural tramadol, tramadol-lidocaine and lidocaine in goats. Vet Anaesth Analg. 2012;39(1):106–11.

57. Aarnes TK, Hubbell JAE, Lerche P, Bednarski RM: Comparison of invasive and oscillometric blood pressure measurement techniques in anesthetized sheep, goats, and cattle. Vet Anaesth Analg. 2014;41(2):174–85.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.